ReviewBrain and behavior2026
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP): A Comprehensive Review of Types, Pathophysiology, and Treatment Approaches.
Review in Brain and behavior, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewThis review aims to provide a comprehensive analysis of chronic inflammatory demyelinating polyneuropathy (CIDP), focusing on its clinical manifestations, pathophysiology, and treatment advancements, with particular emphasis on efgartigimod as a novel therapeutic agent. RECENT
findingsCIDP is a chronic autoimmune disorder caused by demyelination and axonal degeneration, leading to progressive weakness and impaired sensory function. While conventional treatments, including corticosteroids, IVIg, and plasma exchange, provide symptomatic relief, their limitations include significant side effects and resistance in some cases. Efgartigimod, an FcRn blocker targeting the IgG catabolic pathway, has emerged as a promising therapy. The ADHERE study demonstrated a 61% reduction in CIDP relapses with efgartigimod, alongside improved disability scores and a favorable safety profile. SUMMARY: CIDP presents significant diagnostic and therapeutic challenges, requiring tailored approaches to management. Efgartigimod introduces a targeted mechanism of action, offering hope for patients unresponsive to traditional therapies. Further research is needed to establish its long-term efficacy and optimal role in CIDP treatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.